BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
The clonal immunoglobulin molecule, idiotype (ID), expressed on the surface of B-cell malignancies can function as a tumor-specific antigen. BiovaxID is a patient-specific therapeutic cancer vaccine composed of the tumor idiotype conjugated to a carrier protein, keyhole limpet hemocyanin (KLH). In a Phase II clinical trial, administration of ID-KLH vaccine together with granulocyte-macrophage colony-stimulating factor to follicular lymphoma patients in complete remission induced tumor-specific cellular and humoral immunity and molecular remissions, and was associated with prolonged disease-free survival. A randomized, double-blind, Phase III clinical trial is ongoing to definitively determine the clinical benefit of BiovaxID plus granulocyte-macrophage colony-stimulating factor vaccination in patients with follicular lymphoma.
Lee
Seung-Tae
ST
The University of Texas M. D. Anderson Cancer Center, Department of Lymphoma and Myeloma, Division of Cancer Medicine, 1515 Holcombe Blvd, Unit 903, Houston, TX, 77030 USA. stlee@mdanderson.org
Jiang
Yun-Fang
YF
Park
Keon-Uk
KU
Woo
Alison F
AF
Neelapu
Sattva S
SS
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002999:Clone Cells; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000517:prevention & control*
D019496:Cancer Vaccines; D015507:Drugs, Investigational; D007130:Immunoglobulin Idiotypes